279 related articles for article (PubMed ID: 27346133)
41. Tangeretin from Citrus reticulate Inhibits Respiratory Syncytial Virus Replication and Associated Inflammation in Vivo.
Xu JJ; Liu Z; Tang W; Wang GC; Chung HY; Liu QY; Zhuang L; Li MM; Li YL
J Agric Food Chem; 2015 Nov; 63(43):9520-7. PubMed ID: 26468759
[TBL] [Abstract][Full Text] [Related]
42. Inhibition of viral replication reverses respiratory syncytial virus-induced NF-kappaB activation and interleukin-8 gene expression in A549 cells.
Fiedler MA; Wernke-Dollries K; Stark JM
J Virol; 1996 Dec; 70(12):9079-82. PubMed ID: 8971048
[TBL] [Abstract][Full Text] [Related]
43. Antiviral effect of emodin from Rheum palmatum against coxsakievirus B5 and human respiratory syncytial virus in vitro.
Liu Z; Ma N; Zhong Y; Yang ZQ
J Huazhong Univ Sci Technolog Med Sci; 2015 Dec; 35(6):916-922. PubMed ID: 26670446
[TBL] [Abstract][Full Text] [Related]
44. Inhibition of Akt kinase activity suppresses entry and replication of influenza virus.
Hirata N; Suizu F; Matsuda-Lennikov M; Edamura T; Bala J; Noguchi M
Biochem Biophys Res Commun; 2014 Jul; 450(1):891-8. PubMed ID: 24971535
[TBL] [Abstract][Full Text] [Related]
45. Resveratrol Inhibits respiratory syncytial virus-induced IL-6 production, decreases viral replication, and downregulates TRIF expression in airway epithelial cells.
Xie XH; Zang N; Li SM; Wang LJ; Deng Y; He Y; Yang XQ; Liu EM
Inflammation; 2012 Aug; 35(4):1392-401. PubMed ID: 22391746
[TBL] [Abstract][Full Text] [Related]
46. Role of hydrogen sulfide in paramyxovirus infections.
Li H; Ma Y; Escaffre O; Ivanciuc T; Komaravelli N; Kelley JP; Coletta C; Szabo C; Rockx B; Garofalo RP; Casola A
J Virol; 2015 May; 89(10):5557-68. PubMed ID: 25740991
[TBL] [Abstract][Full Text] [Related]
47. Suppression of p38 mitogen-activated protein kinase inhibits hepatitis B virus replication in human hepatoma cell: the antiviral role of nitric oxide.
Chang WW; Su IJ; Chang WT; Huang W; Lei HY
J Viral Hepat; 2008 Jul; 15(7):490-7. PubMed ID: 18221299
[TBL] [Abstract][Full Text] [Related]
48. Alleviation of respiratory syncytial virus replication and inflammation by fungal immunomodulatory protein FIP-fve from Flammulina velutipes.
Chang YC; Chow YH; Sun HL; Liu YF; Lee YT; Lue KH; Ko JL
Antiviral Res; 2014 Oct; 110():124-31. PubMed ID: 25131377
[TBL] [Abstract][Full Text] [Related]
49. Marked induction of matrix metalloproteinase-10 by respiratory syncytial virus infection in human nasal epithelial cells.
Hirakawa S; Kojima T; Obata K; Okabayashi T; Yokota S; Nomura K; Obonai T; Fuchimoto J; Himi T; Tsutsumi H; Sawada N
J Med Virol; 2013 Dec; 85(12):2141-50. PubMed ID: 24009192
[TBL] [Abstract][Full Text] [Related]
50. LncRNA MEG3 ameliorates respiratory syncytial virus infection by suppressing TLR4 signaling.
Tao XW; Zeng LK; Wang HZ; Liu HC
Mol Med Rep; 2018 Mar; 17(3):4138-4144. PubMed ID: 29257348
[TBL] [Abstract][Full Text] [Related]
51. Receptor tyrosine kinase inhibitors block proliferation of TGEV mainly through p38 mitogen-activated protein kinase pathways.
Dong W; Xie W; Liu Y; Sui B; Zhang H; Liu L; Tan Y; Tong X; Fu ZF; Yin P; Fang L; Peng G
Antiviral Res; 2020 Jan; 173():104651. PubMed ID: 31751591
[TBL] [Abstract][Full Text] [Related]
52. Drug candidates and model systems in respiratory syncytial virus antiviral drug discovery.
Heylen E; Neyts J; Jochmans D
Biochem Pharmacol; 2017 Mar; 127():1-12. PubMed ID: 27659812
[TBL] [Abstract][Full Text] [Related]
53. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.
Wu H; Pfarr DS; Johnson S; Brewah YA; Woods RM; Patel NK; White WI; Young JF; Kiener PA
J Mol Biol; 2007 May; 368(3):652-65. PubMed ID: 17362988
[TBL] [Abstract][Full Text] [Related]
54. Inhibition of highly pathogenic avian influenza (HPAI) virus by a peptide derived from vFLIP through its direct destabilization of viruses.
Moon HJ; Nikapitiya C; Lee HC; Park ME; Kim JH; Kim TH; Yoon JE; Cho WK; Ma JY; Kim CJ; Jung JU; Lee JS
Sci Rep; 2017 Jul; 7(1):4875. PubMed ID: 28687749
[TBL] [Abstract][Full Text] [Related]
55. Repurposing Kinase Inhibitors as Antiviral Agents to Control Influenza A Virus Replication.
Perwitasari O; Yan X; O'Donnell J; Johnson S; Tripp RA
Assay Drug Dev Technol; 2015 Dec; 13(10):638-49. PubMed ID: 26192013
[TBL] [Abstract][Full Text] [Related]
56. Novel influenza virus NS1 antagonists block replication and restore innate immune function.
Basu D; Walkiewicz MP; Frieman M; Baric RS; Auble DT; Engel DA
J Virol; 2009 Feb; 83(4):1881-91. PubMed ID: 19052087
[TBL] [Abstract][Full Text] [Related]
57. High-Throughput Hit Screening Cascade to Identify Respiratory Syncytial Virus (RSV) Inhibitors.
Plant H; Stacey C; Tiong-Yip CL; Walsh J; Yu Q; Rich K
J Biomol Screen; 2015 Jun; 20(5):597-605. PubMed ID: 25656237
[TBL] [Abstract][Full Text] [Related]
58. Virus-induced p38 MAPK activation facilitates viral infection.
Cheng Y; Sun F; Wang L; Gao M; Xie Y; Sun Y; Liu H; Yuan Y; Yi W; Huang Z; Yan H; Peng K; Wu Y; Cao Z
Theranostics; 2020; 10(26):12223-12240. PubMed ID: 33204339
[No Abstract] [Full Text] [Related]
59. p38 and OGT sequestration into viral inclusion bodies in cells infected with human respiratory syncytial virus suppresses MK2 activities and stress granule assembly.
Fricke J; Koo LY; Brown CR; Collins PL
J Virol; 2013 Feb; 87(3):1333-47. PubMed ID: 23152511
[TBL] [Abstract][Full Text] [Related]
60. Substituted N-(4-amino-2-chlorophenyl)-5-chloro-2-hydroxybenzamide analogues potently inhibit respiratory syncytial virus (RSV) replication and RSV infection-associated inflammatory responses.
Xu J; Wu W; Chen H; Xue Y; Bao X; Zhou J
Bioorg Med Chem; 2021 Jun; 39():116157. PubMed ID: 33895704
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
